Loading clinical trials...
Loading clinical trials...
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN, AND SEPARATELY PF-07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM
Conditions
Interventions
PF-07081532
Placebo
+1 more
Locations
90
United States
Trinity Clinical Research
Centreville, Alabama, United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
San Fernando Valley Health Institute
Canoga Park, California, United States
Catalina Research Institute, LLC
Montclair, California, United States
Empire Clinical Research
Pomona, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
Start Date
October 27, 2022
Primary Completion Date
July 14, 2023
Completion Date
September 22, 2023
Last Updated
August 1, 2024
NCT07351045
NCT07037459
NCT07508241
NCT07244458
NCT07311850
NCT07395687
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions